PDF(Pubmed)
Abstract：
UNASSIGNED: Esophageal Squamous Cell Carcinoma (ESCC) contributes to the global burden of disease. Conventional treatments such as surgical resection and chemotherapy offer limited long-term survival rates. Recently, immunotherapies targeting PD-1 have shown promise in other cancers, but their efficacy in ESCC remains unclear.
UNASSIGNED: The 31 studies eligible for this study included a total of 10,681 patients who were subjected to immunotherapy, either alone or in combination with traditional chemotherapy. A comprehensive search was conducted on September 1, 2023, across databases including CENTRAL, PubMed, MEDLINE, Web of Science, Embase, and Scopus.
UNASSIGNED: For OSR, results indicate a significantly improved survival at different time points (6, 12, and 24 months), with an odds ratio of 0.636 (95 % CI 0.595-0.680; Z = -13.292; p < 0.00001). In terms of PFS, PD-1 inhibitors demonstrated improvements at different time points; pooled odds ratio was 0.568 (95 % CI 0.511-0.633; Z = -10.357; p < 0.00001). Regarding ORR, the pooled analysis showed an overall odds ratio of 1.724 (95 % CI 1.554-1.913; Z = 10.289; p < 0.00001), indicating improved treatment response. DCR did not suggest a significant advantage for PD-1 inhibitors over chemotherapy, with an odds ratio of 0.904 (95 % CI 0.784-1.043; Z = -1.381; p = 0.167).
UNASSIGNED: There is compelling evidence reinforcing the efficacy and safety of PD-1 inhibitors, as monotherapy or in combination with chemotherapy, for the treatment of ESCC. PD-1 inhibitors demonstrate a significant advantage in terms of OSR, PFS, and ORR.
UNASSIGNED: The 31 studies eligible for this study included a total of 10,681 patients who were subjected to immunotherapy, either alone or in combination with traditional chemotherapy. A comprehensive search was conducted on September 1, 2023, across databases including CENTRAL, PubMed, MEDLINE, Web of Science, Embase, and Scopus.
UNASSIGNED: For OSR, results indicate a significantly improved survival at different time points (6, 12, and 24 months), with an odds ratio of 0.636 (95 % CI 0.595-0.680; Z = -13.292; p < 0.00001). In terms of PFS, PD-1 inhibitors demonstrated improvements at different time points; pooled odds ratio was 0.568 (95 % CI 0.511-0.633; Z = -10.357; p < 0.00001). Regarding ORR, the pooled analysis showed an overall odds ratio of 1.724 (95 % CI 1.554-1.913; Z = 10.289; p < 0.00001), indicating improved treatment response. DCR did not suggest a significant advantage for PD-1 inhibitors over chemotherapy, with an odds ratio of 0.904 (95 % CI 0.784-1.043; Z = -1.381; p = 0.167).
UNASSIGNED: There is compelling evidence reinforcing the efficacy and safety of PD-1 inhibitors, as monotherapy or in combination with chemotherapy, for the treatment of ESCC. PD-1 inhibitors demonstrate a significant advantage in terms of OSR, PFS, and ORR.
摘要：
■食管鳞状细胞癌（ESCC）是全球疾病负担的原因。诸如手术切除和化学疗法的常规治疗提供有限的长期存活率。最近,针对PD-1的免疫疗法在其他癌症中显示出希望，但其在ESCC中的疗效尚不清楚.
■符合这项研究条件的31项研究包括总共10,681名接受免疫治疗的患者。单独或与传统化疗联合使用。2023年9月1日，在包括CENTRAL在内的数据库中进行了全面搜索，PubMed,MEDLINE,WebofScience,Embase,还有Scopus.
■对于OSR，结果表明，在不同时间点（6、12和24个月）的生存率显着提高，比值比为0.636（95%CI0.595-0.680；Z=-13.292；p<0.00001）。就PFS而言,PD-1抑制剂在不同时间点表现出改善；合并比值比为0.568（95％CI0.511-0.633；Z=-10.357；p<0.00001）。关于ORR,汇总分析显示总比值比为1.724(95%CI1.554-1.913;Z=10.289;p<0.00001)，表明治疗反应改善。DCR并不表明PD-1抑制剂比化疗有显著优势，比值比为0.904（95%CI0.784-1.043；Z=-1.381；p=0.167）。
■有令人信服的证据加强了PD-1抑制剂的有效性和安全性，作为单一疗法或与化疗联合，用于ESCC的治疗。PD-1抑制剂在OSR方面表现出显著优势，PFS,ORR。
■符合这项研究条件的31项研究包括总共10,681名接受免疫治疗的患者。单独或与传统化疗联合使用。2023年9月1日，在包括CENTRAL在内的数据库中进行了全面搜索，PubMed,MEDLINE,WebofScience,Embase,还有Scopus.
■对于OSR，结果表明，在不同时间点（6、12和24个月）的生存率显着提高，比值比为0.636（95%CI0.595-0.680；Z=-13.292；p<0.00001）。就PFS而言,PD-1抑制剂在不同时间点表现出改善；合并比值比为0.568（95％CI0.511-0.633；Z=-10.357；p<0.00001）。关于ORR,汇总分析显示总比值比为1.724(95%CI1.554-1.913;Z=10.289;p<0.00001)，表明治疗反应改善。DCR并不表明PD-1抑制剂比化疗有显著优势，比值比为0.904（95%CI0.784-1.043；Z=-1.381；p=0.167）。
■有令人信服的证据加强了PD-1抑制剂的有效性和安全性，作为单一疗法或与化疗联合，用于ESCC的治疗。PD-1抑制剂在OSR方面表现出显著优势，PFS,ORR。
